• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    Amendment: SEC Form SCHEDULE 13D/A filed by Fortrea Holdings Inc.

    5/12/25 9:50:19 PM ET
    $FTRE
    Medical Specialities
    Health Care
    Get the next $FTRE alert in real time by email



    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549


    SCHEDULE 13D

    Under the Securities Exchange Act of 1934

    (Amendment No. 5)


    Fortrea Holdings Inc.

    (Name of Issuer)


    Common Stock, $0.001 par value per share

    (Title of Class of Securities)


    34965K107

    (CUSIP Number)


    JEFFREY C. SMITH
    STARBOARD VALUE LP, 777 Third Avenue, 18th Floor
    New York, NY, 10017
    212-845-7977


    ANDREW FREEDMAN, ESQ.
    OLSHAN FROME WOLOSKY LLP, 1325 Avenue of the Americas
    New York, NY, 10019
    212-451-2300


    MEAGAN REDA, ESQ.
    OLSHAN FROME WOLOSKY LLP, 1325 Avenue of the Americas
    New York, NY, 10019
    212-451-2300

    (Name, Address and Telephone Number of Person Authorized to Receive Notices and Communications)
    05/08/2025

    (Date of Event Which Requires Filing of This Statement)


    If the filing person has previously filed a statement on Schedule 13G to report the acquisition that is the subject of this Schedule 13D, and is filing this schedule because of §§ 240.13d-1(e), 240.13d-1(f) or 240.13d-1(g), check the following box. Checkbox not checked

    The information required on the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).






    SCHEDULE 13D

    CUSIP No.
    34965K107


    1 Name of reporting person

    Starboard Value LP
    2Check the appropriate box if a member of a Group (See Instructions)

    Checkbox not checked  (a)
    Checkbox not checked  (b)
    3SEC use only
    4 Source of funds (See Instructions)

    OO
    5 Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)

    Checkbox not checked
    6Citizenship or place of organization

    DELAWARE
    Number of Shares Beneficially Owned by Each Reporting Person With:
    7Sole Voting Power

    2,716,421.00
    8Shared Voting Power

    0.00
    9Sole Dispositive Power

    2,716,421.00
    10Shared Dispositive Power

    0.00
    11Aggregate amount beneficially owned by each reporting person

    2,716,421.00
    12Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)

    Checkbox not checked
    13Percent of class represented by amount in Row (11)

    3.0 %
    14Type of Reporting Person (See Instructions)

    PN



    SCHEDULE 13D

    CUSIP No.
    34965K107


    1 Name of reporting person

    STARBOARD VALUE & OPPORTUNITY MASTER FUND LTD
    2Check the appropriate box if a member of a Group (See Instructions)

    Checkbox not checked  (a)
    Checkbox not checked  (b)
    3SEC use only
    4 Source of funds (See Instructions)

    WC
    5 Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)

    Checkbox not checked
    6Citizenship or place of organization

    CAYMAN ISLANDS
    Number of Shares Beneficially Owned by Each Reporting Person With:
    7Sole Voting Power

    1,607,516.00
    8Shared Voting Power

    0.00
    9Sole Dispositive Power

    1,607,516.00
    10Shared Dispositive Power

    0.00
    11Aggregate amount beneficially owned by each reporting person

    1,607,516.00
    12Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)

    Checkbox not checked
    13Percent of class represented by amount in Row (11)

    1.8 %
    14Type of Reporting Person (See Instructions)

    CO



    SCHEDULE 13D

    CUSIP No.
    34965K107


    1 Name of reporting person

    STARBOARD VALUE & OPPORTUNITY S LLC
    2Check the appropriate box if a member of a Group (See Instructions)

    Checkbox not checked  (a)
    Checkbox not checked  (b)
    3SEC use only
    4 Source of funds (See Instructions)

    WC
    5 Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)

    Checkbox not checked
    6Citizenship or place of organization

    DELAWARE
    Number of Shares Beneficially Owned by Each Reporting Person With:
    7Sole Voting Power

    204,115.00
    8Shared Voting Power

    0.00
    9Sole Dispositive Power

    204,115.00
    10Shared Dispositive Power

    0.00
    11Aggregate amount beneficially owned by each reporting person

    204,115.00
    12Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)

    Checkbox not checked
    13Percent of class represented by amount in Row (11)

    0.2 %
    14Type of Reporting Person (See Instructions)

    OO



    SCHEDULE 13D

    CUSIP No.
    34965K107


    1 Name of reporting person

    Starboard Value & Opportunity C LP
    2Check the appropriate box if a member of a Group (See Instructions)

    Checkbox not checked  (a)
    Checkbox not checked  (b)
    3SEC use only
    4 Source of funds (See Instructions)

    5 Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)

    Checkbox not checked
    6Citizenship or place of organization

    DELAWARE
    Number of Shares Beneficially Owned by Each Reporting Person With:
    7Sole Voting Power

    0.00
    8Shared Voting Power

    0.00
    9Sole Dispositive Power

    0.00
    10Shared Dispositive Power

    0.00
    11Aggregate amount beneficially owned by each reporting person

    0.00
    12Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)

    Checkbox not checked
    13Percent of class represented by amount in Row (11)

    0 %
    14Type of Reporting Person (See Instructions)

    PN



    SCHEDULE 13D

    CUSIP No.
    34965K107


    1 Name of reporting person

    Starboard Value R LP
    2Check the appropriate box if a member of a Group (See Instructions)

    Checkbox not checked  (a)
    Checkbox not checked  (b)
    3SEC use only
    4 Source of funds (See Instructions)

    5 Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)

    Checkbox not checked
    6Citizenship or place of organization

    DELAWARE
    Number of Shares Beneficially Owned by Each Reporting Person With:
    7Sole Voting Power

    0.00
    8Shared Voting Power

    0.00
    9Sole Dispositive Power

    0.00
    10Shared Dispositive Power

    0.00
    11Aggregate amount beneficially owned by each reporting person

    0.00
    12Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)

    Checkbox not checked
    13Percent of class represented by amount in Row (11)

    0 %
    14Type of Reporting Person (See Instructions)

    PN



    SCHEDULE 13D

    CUSIP No.
    34965K107


    1 Name of reporting person

    Starboard Value & Opportunity Master Fund L LP
    2Check the appropriate box if a member of a Group (See Instructions)

    Checkbox not checked  (a)
    Checkbox not checked  (b)
    3SEC use only
    4 Source of funds (See Instructions)

    WC
    5 Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)

    Checkbox not checked
    6Citizenship or place of organization

    CAYMAN ISLANDS
    Number of Shares Beneficially Owned by Each Reporting Person With:
    7Sole Voting Power

    85,307.00
    8Shared Voting Power

    0.00
    9Sole Dispositive Power

    85,307.00
    10Shared Dispositive Power

    0.00
    11Aggregate amount beneficially owned by each reporting person

    85,307.00
    12Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)

    Checkbox not checked
    13Percent of class represented by amount in Row (11)

    0.1 %
    14Type of Reporting Person (See Instructions)

    PN



    SCHEDULE 13D

    CUSIP No.
    34965K107


    1 Name of reporting person

    Starboard Value L LP
    2Check the appropriate box if a member of a Group (See Instructions)

    Checkbox not checked  (a)
    Checkbox not checked  (b)
    3SEC use only
    4 Source of funds (See Instructions)

    OO
    5 Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)

    Checkbox not checked
    6Citizenship or place of organization

    DELAWARE
    Number of Shares Beneficially Owned by Each Reporting Person With:
    7Sole Voting Power

    85,307.00
    8Shared Voting Power

    0.00
    9Sole Dispositive Power

    85,307.00
    10Shared Dispositive Power

    0.00
    11Aggregate amount beneficially owned by each reporting person

    85,307.00
    12Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)

    Checkbox not checked
    13Percent of class represented by amount in Row (11)

    0.1 %
    14Type of Reporting Person (See Instructions)

    PN



    SCHEDULE 13D

    CUSIP No.
    34965K107


    1 Name of reporting person

    Starboard Value R GP LLC
    2Check the appropriate box if a member of a Group (See Instructions)

    Checkbox not checked  (a)
    Checkbox not checked  (b)
    3SEC use only
    4 Source of funds (See Instructions)

    OO
    5 Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)

    Checkbox not checked
    6Citizenship or place of organization

    DELAWARE
    Number of Shares Beneficially Owned by Each Reporting Person With:
    7Sole Voting Power

    85,307.00
    8Shared Voting Power

    0.00
    9Sole Dispositive Power

    85,307.00
    10Shared Dispositive Power

    0.00
    11Aggregate amount beneficially owned by each reporting person

    85,307.00
    12Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)

    Checkbox not checked
    13Percent of class represented by amount in Row (11)

    0.1 %
    14Type of Reporting Person (See Instructions)

    OO



    SCHEDULE 13D

    CUSIP No.
    34965K107


    1 Name of reporting person

    Starboard X Master Fund Ltd
    2Check the appropriate box if a member of a Group (See Instructions)

    Checkbox not checked  (a)
    Checkbox not checked  (b)
    3SEC use only
    4 Source of funds (See Instructions)

    WC
    5 Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)

    Checkbox not checked
    6Citizenship or place of organization

    CAYMAN ISLANDS
    Number of Shares Beneficially Owned by Each Reporting Person With:
    7Sole Voting Power

    502,805.00
    8Shared Voting Power

    0.00
    9Sole Dispositive Power

    502,805.00
    10Shared Dispositive Power

    0.00
    11Aggregate amount beneficially owned by each reporting person

    502,805.00
    12Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)

    Checkbox not checked
    13Percent of class represented by amount in Row (11)

    0.6 %
    14Type of Reporting Person (See Instructions)

    CO



    SCHEDULE 13D

    CUSIP No.
    34965K107


    1 Name of reporting person

    Starboard Value GP LLC
    2Check the appropriate box if a member of a Group (See Instructions)

    Checkbox not checked  (a)
    Checkbox not checked  (b)
    3SEC use only
    4 Source of funds (See Instructions)

    OO
    5 Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)

    Checkbox not checked
    6Citizenship or place of organization

    DELAWARE
    Number of Shares Beneficially Owned by Each Reporting Person With:
    7Sole Voting Power

    2,716,421.00
    8Shared Voting Power

    0.00
    9Sole Dispositive Power

    2,716,421.00
    10Shared Dispositive Power

    0.00
    11Aggregate amount beneficially owned by each reporting person

    2,716,421.00
    12Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)

    Checkbox not checked
    13Percent of class represented by amount in Row (11)

    3.0 %
    14Type of Reporting Person (See Instructions)

    OO



    SCHEDULE 13D

    CUSIP No.
    34965K107


    1 Name of reporting person

    Starboard Principal Co LP
    2Check the appropriate box if a member of a Group (See Instructions)

    Checkbox not checked  (a)
    Checkbox not checked  (b)
    3SEC use only
    4 Source of funds (See Instructions)

    OO
    5 Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)

    Checkbox not checked
    6Citizenship or place of organization

    DELAWARE
    Number of Shares Beneficially Owned by Each Reporting Person With:
    7Sole Voting Power

    2,716,421.00
    8Shared Voting Power

    0.00
    9Sole Dispositive Power

    2,716,421.00
    10Shared Dispositive Power

    0.00
    11Aggregate amount beneficially owned by each reporting person

    2,716,421.00
    12Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)

    Checkbox not checked
    13Percent of class represented by amount in Row (11)

    3.0 %
    14Type of Reporting Person (See Instructions)

    PN



    SCHEDULE 13D

    CUSIP No.
    34965K107


    1 Name of reporting person

    Starboard Principal Co GP LLC
    2Check the appropriate box if a member of a Group (See Instructions)

    Checkbox not checked  (a)
    Checkbox not checked  (b)
    3SEC use only
    4 Source of funds (See Instructions)

    OO
    5 Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)

    Checkbox not checked
    6Citizenship or place of organization

    DELAWARE
    Number of Shares Beneficially Owned by Each Reporting Person With:
    7Sole Voting Power

    2,716,421.00
    8Shared Voting Power

    0.00
    9Sole Dispositive Power

    2,716,421.00
    10Shared Dispositive Power

    0.00
    11Aggregate amount beneficially owned by each reporting person

    2,716,421.00
    12Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)

    Checkbox not checked
    13Percent of class represented by amount in Row (11)

    3.0 %
    14Type of Reporting Person (See Instructions)

    OO



    SCHEDULE 13D

    CUSIP No.
    34965K107


    1 Name of reporting person

    Smith Jeffrey C
    2Check the appropriate box if a member of a Group (See Instructions)

    Checkbox not checked  (a)
    Checkbox not checked  (b)
    3SEC use only
    4 Source of funds (See Instructions)

    OO
    5 Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)

    Checkbox not checked
    6Citizenship or place of organization

    UNITED STATES
    Number of Shares Beneficially Owned by Each Reporting Person With:
    7Sole Voting Power

    0.00
    8Shared Voting Power

    2,716,421.00
    9Sole Dispositive Power

    0.00
    10Shared Dispositive Power

    2,716,421.00
    11Aggregate amount beneficially owned by each reporting person

    2,716,421.00
    12Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)

    Checkbox not checked
    13Percent of class represented by amount in Row (11)

    3.0 %
    14Type of Reporting Person (See Instructions)

    IN



    SCHEDULE 13D

    CUSIP No.
    34965K107


    1 Name of reporting person

    Feld Peter A
    2Check the appropriate box if a member of a Group (See Instructions)

    Checkbox not checked  (a)
    Checkbox not checked  (b)
    3SEC use only
    4 Source of funds (See Instructions)

    OO
    5 Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)

    Checkbox not checked
    6Citizenship or place of organization

    UNITED STATES
    Number of Shares Beneficially Owned by Each Reporting Person With:
    7Sole Voting Power

    0.00
    8Shared Voting Power

    2,716,421.00
    9Sole Dispositive Power

    0.00
    10Shared Dispositive Power

    2,716,421.00
    11Aggregate amount beneficially owned by each reporting person

    2,716,421.00
    12Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)

    Checkbox not checked
    13Percent of class represented by amount in Row (11)

    3.0 %
    14Type of Reporting Person (See Instructions)

    IN



    SCHEDULE 13D

    Item 1.Security and Issuer
    (a)Title of Class of Securities:

    Common Stock, $0.001 par value per share
    (b)Name of Issuer:

    Fortrea Holdings Inc.
    (c)Address of Issuer's Principal Executive Offices:

    8 MOORE DRIVE, DURHAM, NORTH CAROLINA , 27709.
    Item 1 Comment:
    The following constitutes Amendment No. 5 to the Schedule 13D filed by the undersigned ("Amendment No. 5"). This Amendment No. 5 amends the Schedule 13D as specifically set forth herein. Unless otherwise defined herein, all capitalized terms used herein shall have the meanings given to them in the Schedule 13D.
    Item 3.Source and Amount of Funds or Other Consideration
     
    Item 3 is hereby amended and restated to read as follows: The securities of the Issuer purchased by each of Starboard V&O Fund, Starboard S LLC, Starboard L Master, Starboard X Master and held in the Starboard Value LP Account were purchased with working capital (which may, at any given time, include margin loans made by brokerage firms in the ordinary course of business) in open market purchases, except as otherwise noted. The aggregate purchase price of the 1,607,516 Shares beneficially owned by Starboard V&O Fund is approximately $34,287,438, excluding brokerage commissions. The aggregate purchase price of the 204,115 Shares beneficially owned by Starboard S LLC is approximately $4,526,082, excluding brokerage commissions. The aggregate purchase price of the 85,307 Shares beneficially owned by Starboard L Master is approximately $1,927,093, excluding brokerage commissions. The aggregate purchase price of the 502,805 Shares beneficially owned by Starboard X Master is approximately $11,104,641, excluding brokerage commissions. The aggregate purchase price of the 316,678 Shares held in the Starboard Value LP Account is approximately $6,132,635, excluding brokerage commissions.
    Item 5.Interest in Securities of the Issuer
    (a)
    Item 5(a) is hereby amended and restated to read as follows: The percentages used in this Schedule 13D are based upon 90,500,000 Shares outstanding, as of May 8, 2025, as reported in the Issuer's Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission on May 12, 2025. See rows (11) and (13) of the cover pages to this Schedule 13D for the aggregate number of Shares and percentage of the Shares beneficially owned by each of the Reporting Persons. The filing of this Schedule 13D shall not be deemed an admission that the Reporting Persons are, for purposes of Section 13(d) of the Securities Exchange Act of 1934, as amended, the beneficial owners of any securities of the Issuer that he or it does not directly own. Each of the Reporting Persons specifically disclaims beneficial ownership of the securities reported herein that he or it does not directly own.
    (b)
    Item 5(b) is hereby amended and restated to read as follows: See rows (7) through (10) of the cover pages to this Schedule 13D for the number of Shares as to which each Reporting Person has the sole or shared power to vote or direct the vote and the sole or shared power to dispose or to direct the disposition.
    (c)
    Item 5(c) is hereby amended and restated to read as follows: Information concerning transactions in the securities of the Issuer effected by the Reporting Persons during the past sixty days is set forth in Exhibit 1 attached hereto and is incorporated herein by reference. Except as otherwise noted, all of the transactions in the securities of the Issuer listed therein were effected in the open market through various brokerage entities.
    (e)
    Item 5(e) is hereby amended and restated to read as follows: As of May 8, 2025, the Reporting Persons ceased to beneficially own more than 5% of the outstanding Shares of the Issuer.
    Item 7.Material to be Filed as Exhibits.
     
    Item 7 is hereby amended to add the following exhibit: 1 - Transactions in the Securities.

        SIGNATURE 
     
    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

     
    Starboard Value LP
     
    Signature:/s/ Lindsey Cara
    Name/Title:Lindsey Cara, Authorized Signatory of Starboard Value GP LLC, its general partner
    Date:05/12/2025
     
    STARBOARD VALUE & OPPORTUNITY MASTER FUND LTD
     
    Signature:/s/ Lindsey Cara
    Name/Title:Lindsey Cara, Authorized Signatory of Starboard Value LP, its investment manager
    Date:05/12/2025
     
    STARBOARD VALUE & OPPORTUNITY S LLC
     
    Signature:/s/ Lindsey Cara
    Name/Title:Lindsey Cara, Authorized Signatory of Starboard Value LP, its manager
    Date:05/12/2025
     
    Starboard Value & Opportunity C LP
     
    Signature:/s/ Lindsey Cara
    Name/Title:Lindsey Cara, Authorized Signatory of Starboard Value R LP, its general partner
    Date:05/12/2025
     
    Starboard Value R LP
     
    Signature:/s/ Lindsey Cara
    Name/Title:Lindsey Cara, Authorized Signatory of Starboard Value R GP LLC, its general partner
    Date:05/12/2025
     
    Starboard Value & Opportunity Master Fund L LP
     
    Signature:/s/ Lindsey Cara
    Name/Title:Lindsey Cara, Authorized Signatory of Starboard Value L LP, its general partner
    Date:05/12/2025
     
    Starboard Value L LP
     
    Signature:/s/ Lindsey Cara
    Name/Title:Lindsey Cara, Authorized Signatory of Starboard Value R GP LLC, its general partner
    Date:05/12/2025
     
    Starboard Value R GP LLC
     
    Signature:/s/ Lindsey Cara
    Name/Title:Lindsey Cara, Authorized Signatory
    Date:05/12/2025
     
    Starboard X Master Fund Ltd
     
    Signature:/s/ Lindsey Cara
    Name/Title:Lindsey Cara, Authorized Signatory of Starboard Value LP, its investment manager
    Date:05/12/2025
     
    Starboard Value GP LLC
     
    Signature:/s/ Lindsey Cara
    Name/Title:Lindsey Cara, Authorized Signatory of Starboard Principal Co LP, its member
    Date:05/12/2025
     
    Starboard Principal Co LP
     
    Signature:/s/ Lindsey Cara
    Name/Title:Lindsey Cara, Authorized Signatory of Starboard Principal Co GP LLC, its general partner
    Date:05/12/2025
     
    Starboard Principal Co GP LLC
     
    Signature:/s/ Lindsey Cara
    Name/Title:Lindsey Cara, Authorized Signatory
    Date:05/12/2025
     
    Smith Jeffrey C
     
    Signature:/s/ Lindsey Cara
    Name/Title:Lindsey Cara, Attorney-in-Fact for Jeffrey C. Smith
    Date:05/12/2025
     
    Feld Peter A
     
    Signature:/s/ Lindsey Cara
    Name/Title:Lindsey Cara, Attorney-in-Fact for Peter A. Feld
    Date:05/12/2025
    Get the next $FTRE alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $FTRE

    DatePrice TargetRatingAnalyst
    5/2/2025$7.00Hold
    Truist
    4/10/2025$6.00Equal Weight → Underweight
    Barclays
    12/11/2024$30.00 → $23.00Buy → Neutral
    Citigroup
    12/6/2024$28.00 → $25.00Outperform → Neutral
    Robert W. Baird
    9/25/2024$25.00 → $21.00Buy → Hold
    Jefferies
    8/8/2024$31.00 → $27.00Outperform → In-line
    Evercore ISI
    7/24/2024$30.00Equal Weight
    Barclays
    6/6/2024$28.00Neutral
    Goldman
    More analyst ratings

    $FTRE
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Fortrea Reports First Quarter 2025 Results

      For the three months ended March 31, 2025, from continuing operations: Revenues of $651.3 millionGAAP net loss of $(562.9) million, inclusive of a non-cash goodwill impairment chargeAdjusted EBITDA of $30.3 millionGAAP and adjusted net (loss) income per diluted share of $(6.25) and $0.02, respectivelyBook-to-bill ratio of 1.02x, resulting in 1.14x book-to-bill for the trailing 12 months DURHAM, N.C., May 12, 2025 (GLOBE NEWSWIRE) -- Fortrea (NASDAQ:FTRE) (the "Company"), a leading global contract research organization (CRO), today reported financial results for the first quarter ended March 31, 2025. "Fortrea's first quarter performance represents a solid start to 2025," sai

      5/12/25 6:40:58 AM ET
      $FTRE
      Medical Specialities
      Health Care
    • Fortrea Announces CEO Stepping Down

      DURHAM, N.C., May 12, 2025 (GLOBE NEWSWIRE) -- Fortrea (NASDAQ:FTRE) (the "Company"), a leading global contract research organization (CRO), today announced that Thomas Pike is stepping down from his role as Fortrea's Chief Executive Officer and as Chairman of its Board. Fortrea's Lead Independent Director, Peter M. Neupert, will serve as Interim Chief Executive Officer and Board Chair, beginning May 13, 2025. As part of a succession planning process, an executive search is already at an advanced stage. Mr. Pike has entered into a consulting agreement with the Company to serve as a resource to its leadership team through the transition. "On behalf of Fortrea's Board, I would like to thank

      5/12/25 6:30:02 AM ET
      $FTRE
      Medical Specialities
      Health Care
    • Fortrea Named a Leader in Everest Group's Pharmacovigilance Operations PEAK Matrix® Assessment 2025

      DURHAM, N.C., May 01, 2025 (GLOBE NEWSWIRE) -- Fortrea (NASDAQ:FTRE), a leading global contract research organization (CRO), today announced it has been recognized as a "Leader" for pharmacovigilance (PV) operations by Everest Group in its annual Pharmacovigilance Operations PEAK Matrix® Assessment 2025. Fortrea's top position was recognized in both pre-and post-approval PV operations in Everest Group's proprietary framework, which assesses market impact along with vision and capability. "Fortrea's mission is to bring life-changing treatments to patients faster, and we have translated our profound commitment to patients into recognized leadership in pharmacovigilance," said Mark Morais, c

      5/1/25 7:00:20 AM ET
      $FTRE
      Medical Specialities
      Health Care

    $FTRE
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • General Counsel Hanson James S. bought $50,600 worth of shares (2,000 units at $25.30), increasing direct ownership by 37% to 7,475 units (SEC Form 4)

      4 - Fortrea Holdings Inc. (0001965040) (Issuer)

      6/12/24 6:28:42 PM ET
      $FTRE
      Medical Specialities
      Health Care
    • Pike Thomas bought $248,066 worth of shares (10,000 units at $24.81), increasing direct ownership by 21% to 57,827 units (SEC Form 4)

      4 - Fortrea Holdings Inc. (0001965040) (Issuer)

      5/30/24 4:34:01 PM ET
      $FTRE
      Medical Specialities
      Health Care

    $FTRE
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Truist initiated coverage on Fortrea with a new price target

      Truist initiated coverage of Fortrea with a rating of Hold and set a new price target of $7.00

      5/2/25 8:14:26 AM ET
      $FTRE
      Medical Specialities
      Health Care
    • Fortrea downgraded by Barclays with a new price target

      Barclays downgraded Fortrea from Equal Weight to Underweight and set a new price target of $6.00

      4/10/25 8:49:08 AM ET
      $FTRE
      Medical Specialities
      Health Care
    • Fortrea downgraded by Citigroup with a new price target

      Citigroup downgraded Fortrea from Buy to Neutral and set a new price target of $23.00 from $30.00 previously

      12/11/24 7:50:50 AM ET
      $FTRE
      Medical Specialities
      Health Care

    $FTRE
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • SEC Form 4 filed by Director Russell Erin L

      4 - Fortrea Holdings Inc. (0001965040) (Issuer)

      3/21/25 6:04:05 PM ET
      $FTRE
      Medical Specialities
      Health Care
    • SEC Form 4 filed by Chief Executive Officer Pike Thomas

      4 - Fortrea Holdings Inc. (0001965040) (Issuer)

      3/21/25 6:01:19 PM ET
      $FTRE
      Medical Specialities
      Health Care
    • General Counsel Hanson James S. converted options into 2,998 shares and sold $9,768 worth of shares (1,007 units at $9.70), increasing direct ownership by 27% to 9,466 units (SEC Form 4)

      4 - Fortrea Holdings Inc. (0001965040) (Issuer)

      3/17/25 4:37:58 PM ET
      $FTRE
      Medical Specialities
      Health Care

    $FTRE
    SEC Filings

    See more
    • Amendment: SEC Form SCHEDULE 13D/A filed by Fortrea Holdings Inc.

      SCHEDULE 13D/A - Fortrea Holdings Inc. (0001965040) (Subject)

      5/12/25 9:50:19 PM ET
      $FTRE
      Medical Specialities
      Health Care
    • SEC Form 10-Q filed by Fortrea Holdings Inc.

      10-Q - Fortrea Holdings Inc. (0001965040) (Filer)

      5/12/25 4:15:19 PM ET
      $FTRE
      Medical Specialities
      Health Care
    • Amendment: SEC Form SCHEDULE 13G/A filed by Fortrea Holdings Inc.

      SCHEDULE 13G/A - Fortrea Holdings Inc. (0001965040) (Subject)

      5/12/25 10:32:18 AM ET
      $FTRE
      Medical Specialities
      Health Care

    $FTRE
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13G filed by Fortrea Holdings Inc.

      SC 13G - Fortrea Holdings Inc. (0001965040) (Subject)

      11/12/24 9:55:14 AM ET
      $FTRE
      Medical Specialities
      Health Care
    • SEC Form SC 13D/A filed by Fortrea Holdings Inc. (Amendment)

      SC 13D/A - Fortrea Holdings Inc. (0001965040) (Subject)

      5/28/24 5:10:47 PM ET
      $FTRE
      Medical Specialities
      Health Care
    • SEC Form SC 13D/A filed by Fortrea Holdings Inc. (Amendment)

      SC 13D/A - Fortrea Holdings Inc. (0001965040) (Subject)

      2/26/24 7:01:18 PM ET
      $FTRE
      Medical Specialities
      Health Care

    $FTRE
    Leadership Updates

    Live Leadership Updates

    See more
    • Society for Clinical Research Sites (SCRS) and Fortrea Partner to Advance Collaboration in Clinical Research

      DURHAM, N.C., Feb. 20, 2025 (GLOBE NEWSWIRE) -- The Society for Clinical Research Sites (SCRS) and Fortrea (NASDAQ:FTRE), a leading global contract research organization (CRO), are pleased to announce Fortrea's sponsorship of the SCRS Collaborate Forward working group. Comprising 16 leading Global Impact Partner organizations, the Collaborate Forward working group will explore and develop best practices to reduce administrative burdens across the clinical research ecosystem. The group is committed to fostering transparency and collaboration to tackle challenges faced by clinical research sites. By improving internal processes, it aims to make sites more sustainable and trials more efficie

      2/20/25 7:00:00 AM ET
      $FTRE
      Medical Specialities
      Health Care
    • Maravai LifeSciences Appoints R. Andrew Eckert as Chairman of the Board of Directors

      SAN DIEGO, Dec. 05, 2024 (GLOBE NEWSWIRE) -- Maravai LifeSciences Holdings, Inc. ("Maravai" or the "Company") (NASDAQ:MRVI), a global provider of life science reagents and services to researchers and biotech innovators, announced that Carl Hull will retire from his position as Executive Chairman of the Board and that the Board of Directors has unanimously elected R. Andrew Eckert to succeed him as Chairman of the Board, effective December 5, 2024. Carl Hull founded Maravai in 2014 and served as Chief Executive Officer, assuming the role of Executive Chairman in October 2022. "Leading Maravai has been the single most rewarding experience in my career. I am extremely proud of what we have

      12/5/24 4:05:00 PM ET
      $BDX
      $FTRE
      $MRVI
      Medical/Dental Instruments
      Health Care
      Medical Specialities
      Biotechnology: Pharmaceutical Preparations
    • Fortrea Appoints Robert Parks as Chief Accounting Officer

      DURHAM, N.C., July 11, 2024 (GLOBE NEWSWIRE) -- Fortrea (NASDAQ:FTRE), a leading global contract research organization (CRO), today announced that Robert "Bobby" Parks has been appointed as chief accounting officer (CAO), responsible for Fortrea's accounting function, including financial reporting, risk, controls and compliance in accordance with applicable standards, laws and regulations. "We are pleased to welcome Bobby to the Fortrea team, bringing his broad and deep experience from CROs and other fast-paced environments," said Fortrea Chief Financial Officer Jill McConnell. "Bobby has a track record of managing Sarbanes-Oxley Act requirements and internal controls, including for CROs,

      7/11/24 8:00:09 AM ET
      $FTRE
      Medical Specialities
      Health Care

    $FTRE
    Financials

    Live finance-specific insights

    See more
    • Fortrea Reports First Quarter 2025 Results

      For the three months ended March 31, 2025, from continuing operations: Revenues of $651.3 millionGAAP net loss of $(562.9) million, inclusive of a non-cash goodwill impairment chargeAdjusted EBITDA of $30.3 millionGAAP and adjusted net (loss) income per diluted share of $(6.25) and $0.02, respectivelyBook-to-bill ratio of 1.02x, resulting in 1.14x book-to-bill for the trailing 12 months DURHAM, N.C., May 12, 2025 (GLOBE NEWSWIRE) -- Fortrea (NASDAQ:FTRE) (the "Company"), a leading global contract research organization (CRO), today reported financial results for the first quarter ended March 31, 2025. "Fortrea's first quarter performance represents a solid start to 2025," sai

      5/12/25 6:40:58 AM ET
      $FTRE
      Medical Specialities
      Health Care
    • Fortrea Announces CEO Stepping Down

      DURHAM, N.C., May 12, 2025 (GLOBE NEWSWIRE) -- Fortrea (NASDAQ:FTRE) (the "Company"), a leading global contract research organization (CRO), today announced that Thomas Pike is stepping down from his role as Fortrea's Chief Executive Officer and as Chairman of its Board. Fortrea's Lead Independent Director, Peter M. Neupert, will serve as Interim Chief Executive Officer and Board Chair, beginning May 13, 2025. As part of a succession planning process, an executive search is already at an advanced stage. Mr. Pike has entered into a consulting agreement with the Company to serve as a resource to its leadership team through the transition. "On behalf of Fortrea's Board, I would like to thank

      5/12/25 6:30:02 AM ET
      $FTRE
      Medical Specialities
      Health Care
    • Fortrea Announces Date for First Quarter 2025 Financial Results and Conference Call

      DURHAM, N.C., April 15, 2025 (GLOBE NEWSWIRE) -- Fortrea (NASDAQ:FTRE) (the "Company"), a leading global contract research organization (CRO), today announced that it will release its first quarter 2025 financial results before the market opens on Monday, May 12, 2025. Fortrea will host a conference call at 9:00 am ET that day to review its financial results and conduct a question-and-answer session. To participate in the earnings call, participants should register online at the Fortrea Investor Relations website. To avoid potential delays, please join at least 10 minutes prior to the start of the call. The conference call can also be accessed through the following earnings webcast link.

      4/15/25 7:00:25 AM ET
      $FTRE
      Medical Specialities
      Health Care